| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology |
1 Department of Urology, Kanazawa University, Kanazawa, Japan;
2 Teikoku Hormone MFG. Co., Kanagawa, Japan; and
3 Unit for Laboratory Animal Medicine and Department of Pathology, University of Michigan, Ann Arbor, Michigan
Despite an initial response to androgen deprivation therapy, prostate cancer (PCa) progresses eventually from an androgen-dependent to an androgen-independent phenotype. One of the mechanisms of relapse is antiandrogen withdrawal phenomenon caused by mutation of 877th amino acid of androgen receptor (AR). In the present study, we established a method to measure the concentration of androstenediol (adiol) in prostate tissue. We found that adiol maintains a high concentration in PCa tissue even after androgen deprivation therapy. Furthermore, adiol is a stronger activator of mutant AR in LNCaP PCa cells and induces more cell proliferation, prostate-specific antigen (PSA) mRNA expression, and PSA promoter than dihydrotestosterone (DHT). Because antiandrogen, bicalutamide, blocked adiol activity in LNCaP cells, it was suggested that adiol effect was mediated through AR. However, high concentration of bicalutamide was necessary to block completely adiol activity. These effects were specific to LNCaP cells because adiol had less effect in PC-3 PCa cells transfected with wild-type AR than DHT and had similar effect in PC-3 cells transfected with mutant AR. The mechanism that adiol activates mutant AR in LNCaP cells did not result from the increased affinity to mutant AR or from AR’s association with coactivator ARA70. However, low concentration of adiol induced more AR nuclear translocation than DHT in LNCaP cells and not PC-3 cells transfected with AR. These results indicate that adiol may cause the progression of PCa even after hormone therapy.
This article has been cited by other articles:
|
|
 |
|
  A. Mizokami, E. Koh, K. Izumi, K. Narimoto, M. Takeda, S. Honma, J. Dai, E. T Keller, and M. Namiki Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone Endocr. Relat. Cancer, December 1, 2009; 16(4): 1139 - 1155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y. Chun, N. Nadiminty, S. Dutt, W. Lou, J. C. Yang, H.-J. Kung, C. P. Evans, and A. C. Gao Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells Clin. Cancer Res., August 1, 2009; 15(15): 4815 - 4822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Hsing, L. W. Chu, and F. Z. Stanczyk Androgen and Prostate Cancer: Is the Hypothesis Dead? Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2525 - 2530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M Day, H. J Tutill, A. Purohit, and M. J Reed Design and validation of specific inhibitors of 17{beta}-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis Endocr. Relat. Cancer, September 1, 2008; 15(3): 665 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hoon Lee, H. Gong, S. Khadem, Y. Lu, X. Gao, S. Li, J. Zhang, and W. Xie Androgen Deprivation by Activating the Liver X Receptor Endocrinology, August 1, 2008; 149(8): 3778 - 3788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Everley, C. A. Gartner, W. Haas, A. Saghatelian, J. E. Elias, B. F. Cravatt, B. R. Zetter, and S. P. Gygi Assessing Enzyme Activities Using Stable Isotope Labeling and Mass Spectrometry Mol. Cell. Proteomics, October 1, 2007; 6(10): 1771 - 1777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Mostaghel, S. T. Page, D. W. Lin, L. Fazli, I. M. Coleman, L. D. True, B. Knudsen, D. L. Hess, C. C. Nelson, A. M. Matsumoto, et al. Intraprostatic Androgens and Androgen-Regulated Gene Expression Persist after Testosterone Suppression: Therapeutic Implications for Castration-Resistant Prostate Cancer Cancer Res., May 15, 2007; 67(10): 5033 - 5041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Stanway, P. Delavault, A. Purohit, L. W. L. Woo, C. Thurieau, B. V. L. Potter, and M. J. Reed Steroid Sulfatase: A New Target for the Endocrine Therapy of Breast Cancer Oncologist, April 1, 2007; 12(4): 370 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Ji, L. Chang, F. Z. Stanczyk, M. Ookhtens, A. Sherrod, and A. Stolz Impaired Dihydrotestosterone Catabolism in Human Prostate Cancer: Critical Role of AKR1C2 as a Pre-Receptor Regulator of Androgen Receptor Signaling Cancer Res., February 1, 2007; 67(3): 1361 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Page, D. W. Lin, E. A. Mostaghel, D. L. Hess, L. D. True, J. K. Amory, P. S. Nelson, A. M. Matsumoto, and W. J. Bremner Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3850 - 3856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gao, X. Ouyang, W. A. Banach-Petrosky, M. M. Shen, and C. Abate-Shen Emergence of Androgen Independence at Early Stages of Prostate Cancer Progression in Nkx3.1; Pten Mice Cancer Res., August 15, 2006; 66(16): 7929 - 7933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Duff and I. J. McEwan Mutation of Histidine 874 in the Androgen Receptor Ligand-Binding Domain Leads to Promiscuous Ligand Activation and Altered p160 Coactivator Interactions Mol. Endocrinol., December 1, 2005; 19(12): 2943 - 2954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Farla, R. Hersmus, J. Trapman, and A. B. Houtsmuller Antiandrogens prevent stable DNA-binding of the androgen receptor J. Cell Sci., September 15, 2005; 118(18): 4187 - 4198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Titus, M. J. Schell, F. B. Lih, K. B. Tomer, and J. L. Mohler Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4653 - 4657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z Culig, H Steiner, G Bartsch, and A Hobisch Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nakamura, T. Suzuki, M. Nakabayashi, M. Endoh, K. Sakamoto, Y. Mikami, T. Moriya, A. Ito, S. Takahashi, S. Yamada, et al. In situ androgen producing enzymes in human prostate cancer Endocr. Relat. Cancer, March 1, 2005; 12(1): 101 - 107. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
